Daily News Podcast

TNF inhibitor linked to one-third drop in total mortality

Publish date: June 18, 2018

 

Receiving a TNF inhibitor for any indications cut patients’ overall mortality rate by more than one-third. Also today, HHS secretary, Alex Azar blames pharmacy benefit managers for no drop in prescription prices, a DEA ruling may have stoked illicit opioid sales, and taking a bisphosphonate holiday that lasts 2 years or longer is linked with increased risk for fracture.

Listen to the MDedge Daily News podcast for all the details on today’s top news.

Recommended Reading

Prostate cancer risk before age 55 higher for black men
MDedge Dermatology
Statin effect in prostate cancer may be caused by reduced inflammation
MDedge Dermatology
Smoking tied to localized prostate cancer recurrence, metastasis, death
MDedge Dermatology
FDA approves rituximab for treating pemphigus vulgaris
MDedge Dermatology
Suicide rate jumps 30%
MDedge Dermatology
New cell-free DNA assays hold promise for lung cancer screening
MDedge Dermatology
Allergies linked to autism spectrum disorder in children
MDedge Dermatology
Study finds widespread use of medications with depression as side effect
MDedge Dermatology
Type 2 diabetes may promote Parkinson development
MDedge Dermatology
Routine AAA screening for older men: more harm than good?
MDedge Dermatology